First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 877-885

  Meulendijks, Didier ^a   Jacob, Wolfgang ^b   Martinez Garcia, Maria ^c   Taus, Alvaro ^c   Lolkema, Martijn P ^d,e   Voest, Emile E ^a   Langenberg, Marlies H G ^d   Kanonnikoff, Tania Fleitas ^f   Cervantes, Andres ^f   De Jonge, Maja J ^e   Sleijfer, Stefan ^e   Soerensen, Morten Mau ^g   Thomas, Marlene ^b   Ceppi, Maurizio ^b   Meneses Lorente, Georgina ^h   James, Ian ^b   Adessi, Celine ⁱ   Michielin, Francesca ⁱ   Abiraj, Keelara ⁱ   Bossenmaier, Birgit ^b   Schellens, Jan H M ^a   Weisser, Martin ^b   Lassen, Ulrik N ^g   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY OF VALENCIA   (Spain)

^g University of Copenhagen   (Denmark)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; LUMRETUZUMAB; ANALGESIC AGENT; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BLADDER CANCER; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; EX VIVO STUDY; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFUSION RELATED REACTION; INSOMNIA; KIDNEY CARCINOMA; MALE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NATURAL KILLER CELL; NAUSEA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PAIN; PANCREAS CANCER; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TRIPLE NEGATIVE BREAST CANCER; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; UTERUS CANCER; VOMITING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTOR, ERBB-3; TREATMENT OUTCOME;

EID: 84964285892     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1683     Document Type: Article

References (33)

1. Campbell MR, Amin D, MoasserMM.HER3 comes of age: New insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-83.
2. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41.
3. Jain A, Penuel E,Mink S, Schmidt J, Hodge A, Favero K, et al.HERkinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010;70:1989-99.
4. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of survivin. Oncogene 2010;29:4225-36.
5. Engelman JA, Zejnullahu K,Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
6. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 2008;27:3944-56.
7. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-65.
8. Muller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, et al. Identification of metastasis-associated receptor tyrosine kinase in non-small cell lung cancer. Cancer Res 2005;65:1778-82.
9. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997;10: 142-8.
10. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-23.
11. Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956-68.
12. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413-48.
13. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011;20:158-72.
14. ShengQ, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. Anactivated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010;17:298-310.
15. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. TargetingADAMmediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50
16. Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS ONE 2013;8:e56765.
17. Mirschberger C, Schiller CB, Schraml M, Dimoudis N, Friess T, Gerdes CA, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013;73: 5183-94.
18. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
20. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Accessed 15/11/2014. Available from: Http://ctep.cancer.gov
21. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, et al. CD56dim CD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005:19:835-40.
22. Meneses-Lorente G, Friess T, Kolm I, Holzlwimmer G, Bader S, Meille C, et al. Preclinical pharmacokinetics, pharmacodynamica, and efficacy of RG7116: A novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol 2015;75:837-50.
23. Denlinger CS, Keedy VL, Cleary JM, Kubasek W, Onsum M, Moulis S, et al. Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors. Cancer Res 2011;71:(8 Suppl).
24. Reynolds KL, Juric D, Baselga J, Maqueda MA, Tabernero J, Bedard PL, et al. A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. J Clin Oncol 2014;32:(suppl; abstr 2517).
25. Sarantopoulos J, Gordon MS, Harvey RD, Sankhala K, Malik L, Mahalingam D, et al. First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors. J Clin Oncol 2014;32:(suppl; abstr 11113).
26. LoRusso P, Janne PA,Oliveira M, Rizvi N, Malburg L, Keedy V, et al. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013;19:3078-87.
27. Bauer TM, Infante JR, Eder JP, LoRusso P, LaVallee T, Gedrich R, et al. A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors. J Clin Oncol 2015;33 (suppl; abstr 2598).
28. Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res 2013;15:R85.
29. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, et al. Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced ormetastatic epithelialtumors.ClinCancerRes 2015;21:2462-70
30. Van Pawel J, Tseng J, Dediu M, Schumann C, Moritz B, Mendell-Harary J, et al. Phase 2 HERALD study of patritumab with erlotinib in advanced NSCLC subjects. J Clin Oncol 2014;32 (suppl; abstr 8045).
31. Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. J Clin Oncol 2014;32 (suppl; abstr 587).
32. Sequist L, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combinationwith erlotinib in EGFR wild-type NSCLC patients. J Clin Oncol 2014;32 (suppl; abstr 8051).
33. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013;3:520-33.